

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.48 Billion in April

保瑞公告 4 月自結合併營收新台幣 14 億 8 仟萬元

Taipei, Taiwan, May 11, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for April 2026 reached NT\$1.48 billion. Year-to-date revenues declined 19.97% year-on-year.

台北，台灣，2026 年 5 月 11 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 4 月自結合併營收為新台幣 14 億 8 仟萬元，1 至 4 月營收較去年衰退 19.97%。

Flagship NDA product VIGAFYDE[®] delivered a strong month, while the Company's leading generic product DLS is showing signs of recovery, having successfully defended market share albeit through a double-digit price concession. Upsher-Smith has brought three new generic products to market year-to-date and continues to navigate a competitive landscape with disciplined commercial execution. Looking ahead, the Company expects a steady upward trend in revenues in the coming months.

旗艦專科用藥 VIGAFYDE[®] 本月營收持續上攻，主力學名藥產品 DLS 亦逐步復甦，Upsher-Smith 在降價雙位數百分比的策略下成功守住市占；今年以來，Upsher-Smith 已上市三項學名藥新產品，正以嚴謹的商業策略因應市場競爭。展望近期幾個月，公司預期營收將爬梯式增長。

About Bora:

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品



質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : Nadiya.Chen@bora-corp.com